Literature DB >> 6207480

Massachusetts Metabolic Disorders Screening Program: III. Sarcosinemia.

H L Levy, J T Coulombe, R Benjamin.   

Abstract

Sarcosinemia has been detected by routine screening of urine for metabolic and transport disorders in Massachusetts. Three infants who had sarcosinemia were detected through the neonatal urine specimen, an observed incidence of 1:350,000. A fourth child had sarcosinemia detected through family screening after his brother was found to have Hartnup disease by neonatal urine screening. These four children with sarcosinemia have plasma sarcosine concentrations ranging from 80 to 603 mumol/L and urine sarcosine from 2.1 to 9.4 mumol/mg of creatinine, findings similar to those reported for persons with sarcosinemia. No treatment has been given. At 3.8 to 15 years of age, the children had normal findings on physical examination and had no specific illnesses. Their full-scale IQ scores ranged from 89 to 111. The oldest child had a learning and emotional disorder, and one other child was emotionally unstable. It was concluded that sarcosinemia as a specific disorder is probably benign and that the mental retardation and dysmorphic features described in some affected persons are likely coincidental with the biochemical defect. The emotional disturbances that were encountered in two children are also probably coincidental but need further attention in this disorder.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6207480

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  9 in total

1.  A patient with sarcosinaemia.

Authors:  F J van Sprang; M Duran; H G Scholten; S K Wadman
Journal:  J Inherit Metab Dis       Date:  1986       Impact factor: 4.982

2.  Sarcosinaemia in a retarded, amaurotic child.

Authors:  A C Sewell; M Krille; I Wilhelm
Journal:  Eur J Pediatr       Date:  1986-02       Impact factor: 3.183

3.  Selective screening for amino acid disorders.

Authors:  M Duran; L Dorland; P K de Bree; R Berger
Journal:  Eur J Pediatr       Date:  1994       Impact factor: 3.183

4.  Mutations in the sarcosine dehydrogenase gene in patients with sarcosinemia.

Authors:  Ifat Bar-joseph; Elon Pras; Haike Reznik-Wolf; Dina Marek-Yagel; Almogit Abu-Horvitz; Maya Dushnitzky; Nurit Goldstein; Shlomit Rienstein; Michal Dekel; Ben Pode-Shakked; Joseph Zlotnik; Anelia Benarrosh; Philippe Gillery; Niklaus Hofliger; Christiane Auray-Blais; Roselyne Garnotel; Yair Anikster
Journal:  Hum Genet       Date:  2012-07-24       Impact factor: 4.132

5.  Hypoglycinaemia and psychomotor delay in a child with xeroderma pigmentosum.

Authors:  E J Quackenbush; K H Kraemer; W A Gahl; V Schirch; D A Whiteman; K Levine; H L Levy
Journal:  J Inherit Metab Dis       Date:  1999-12       Impact factor: 4.982

6.  Prefrontal cortex and spinal cord mediated anti-neuropathy and analgesia induced by sarcosine, a glycine-T1 transporter inhibitor.

Authors:  Maria V Centeno; Amelia Mutso; Magali Millecamps; A Vania Apkarian
Journal:  Pain       Date:  2009-07-03       Impact factor: 6.961

7.  sar: a genetic mouse model for human sarcosinemia generated by ethylnitrosourea mutagenesis.

Authors:  C O Harding; P Williams; D M Pflanzer; R E Colwell; P W Lyne; J A Wolff
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-01       Impact factor: 11.205

8.  Newborn urine screening experience with over one million infants in the Quebec Network of Genetic Medicine.

Authors:  B Lemieux; C Auray-Blais; R Giguère; D Shapcott; C R Scriver
Journal:  J Inherit Metab Dis       Date:  1988       Impact factor: 4.982

9.  Serum methionine metabolites are risk factors for metastatic prostate cancer progression.

Authors:  Sally Stabler; Tatsuki Koyama; Zhiguo Zhao; Magaly Martinez-Ferrer; Robert H Allen; Zigmund Luka; Lioudmila V Loukachevitch; Peter E Clark; Conrad Wagner; Neil A Bhowmick
Journal:  PLoS One       Date:  2011-08-10       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.